Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults
Wan-Hsuan Lu,Kelly Virecoulon Giudici,John E Morley,Sophie Guyonnet,Angelo Parini,Geetika Aggarwal,Andrew D Nguyen,Yan Li,Randall J Bateman,Bruno Vellas,Philipe de Souto Barreto,MAPT/DSA Group,Isabelle Carrié,Lauréane Brigitte,Catherine Faisant,Franҫoise Lala,Julien Delrieu,Hélène Villars,Emeline Combrouze,Carole Badufle,Audrey Zueras,Sandrine Andrieu,Christelle Cantet,Christophe Morin,Gabor Abellan Van Kan,Yves Rolland,Charlotte Dupuy,Céline Caillaud,Pierre-Jean Ousset,Sherry Willis,Sylvie Belleville,Brigitte Gilbert,Francine Fontaine,Jean-François Dartigues,Isabelle Marcet,Fleur Delva,Alexandra Foubert,Sandrine Cerda,Marie-Noëlle Cuffi,Corinne Costes,Olivier Rouaud,Patrick Manckoundia,Valérie Quipourt,Sophie Marilier,Evelyne Franon,Lawrence Bories,Marie-Laure Pader,Marie-France Basset,Bruno Lapoujade,Valérie Faure,Michael Li Yung Tong,Christine Malick-Loiseau,Evelyne Cazaban-Campistron,Franҫoise Desclaux,Colette Blatge,Thierry Dantoine,Cécile Laubarie-Mouret,Isabelle Saulnier,Jean-Pierre Clément,Marie-Agnès Picat,Laurence Bernard-Bourzeix,Stéphanie Willebois,Iléana Désormais,Noëlle Cardinaud,Marc Bonnefoy,Pierre Livet,Pascale Rebaudet,Claire Gédéon,Catherine Burdet,Flavien Terracol,Alain Pesce,Stéphanie Roth,Sylvie Chaillou,Sandrine Louchart,Kristel Sudres,Nicolas Lebrun,Nadège Barro-Belaygues,Jacques Touchon,Karim Bennys,Audrey Gabelle,Aurélia Romano,Lynda Touati,Cécilia Marelli,Cécile Pays,Philippe Robert,Franck Le Duff,Claire Gervais,Sébastien Gonfrier,Yannick Gasnier,Serge Bordes,Danièle Begorre,Christian Carpuat,Khaled Khales,Jean-François Lefebvre,Samira Misbah El Idrissi,Pierre Skolil,Jean-Pierre Salles,Carole Dufouil,Stéphane Lehéricy,Marie Chupin,Jean-François Mangin,Ali Bouhayia,Michèle Allard,Frédéric Ricolfi,Dominique Dubois,Marie Paule Bonceour Martel,Franҫois Cotton,Alain Bonafé,Stéphane Chanalet,Françoise Hugon,Fabrice Bonneville,Christophe Cognard,Franҫois Chollet,Pierre Payoux,Thierry Voisin,Sophie Peiffer,Anne Hitzel,Michel Zanca,Jacques Monteil,Jacques Darcourt,Laurent Molinier,Hélène Derumeaux,Nadège Costa,Bertrand Perret,Claire Vinel,Sylvie Caspar-Bauguil,Pascale Olivier-Abbal,Nicola Coley
DOI: https://doi.org/10.1007/s11357-022-00554-y
GeroScience
Abstract:We investigated combining a core AD neuropathology measure (plasma amyloid-beta [Aβ] 42/40) with five plasma markers of inflammation, cellular stress, and neurodegeneration to predict cognitive decline. Among 401 participants free of dementia (median [IQR] age, 76 [73-80] years) from the Multidomain Alzheimer Preventive Trial (MAPT), 28 (7.0%) participants developed dementia, and 137 (34.2%) had worsening of clinical dementia rating (CDR) scale over 4 years. In the models utilizing plasma Aβ alone, a tenfold increased risk of incident dementia (nonsignificant) and a fivefold increased risk of worsening CDR were observed as each nature log unit increased in plasma Aβ levels. Models incorporating Aβ plus multiple plasma biomarkers performed similarly to models included Aβ alone in predicting dementia and CDR progression. However, improving Aβ model performance for composite cognitive score (CCS) decline, a proxy of dementia, was observed after including plasma monocyte chemoattractant protein 1 (MCP1) and growth differentiation factor 15 (GDF15) as covariates. Participants with abnormal Aβ, GDF15, and MCP1 presented higher CCS decline (worsening cognitive function) compared to their normal-biomarker counterparts (adjusted β [95% CI], - 0.21 [- 0.35 to - 0.06], p = 0.005). In conclusion, our study found limited added values of multi-biomarkers beyond the basic Aβ models for predicting clinically meaningful cognitive decline among non-demented older adults. However, a combined assessment of inflammatory and cellular stress status with Aβ pathology through measuring plasma biomarkers may improve the evaluation of cognitive performance.